Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epeleuton in Sickle Cell Disease
NCT05861453Phase 2Completed
- Sponsor
- Afimmune
- Start
- Jan 2024
- Primary completion
- Jan 2026
- Modality
- Classical Binding Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of epeleuton in sickle cell disease (SCD), sponsored by Afimmune. Started Jan 2024; status: completed.
02
Drugs
epeleuton
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT05861453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05861453.